Diabetic Macular Edema Screened by Handheld Smartphone-based Retinal Camera and Artificial Intelligence
Journal of Medical Systems · 2022-01 · 46 (1)
DOI: 10.1007/s10916-021-01795-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Systems, online erschienen am 11.12.2021. Verfasst von Fernando Korn Malerbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo-SP, Brazil. fernandokmalerbi@gmail.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Macular Edema. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Our aim was to assess the tomographic presence of diabetic macular edema in type 2 diabetes patients screened for diabetic retinopathy with color fundus photographs and an artificial intelligence algorithm. Color fundus photographs obtained with a low-cost smartphone-based handheld retinal camera were analyzed by the algorithm; patients with suspected macular lesions underwent ocular coherence tomography. A total of 366 patients were screened; diabetic macular edema was suspected in 34 and confirmed in 29 individuals, with average age 60.5 ± 10.9 years and glycated hemoglobin 9.8 ± 2.4%; use of insulin, statins, and aspirin were reported in 44.8%, 37.9%, and 34.5% of individuals, respectively; systemic blood hypertension, dyslipidemia, abdominal obesity, chronic kidney disease, and risk for diabetic foot ulcers were present in 100%, 58.6%, 62.1%, 48.3%, and 27.5% of individuals, respectively. Proliferative diabetic retinopathy was present in 31% of patients with macular edema; severity level was associated with albuminuria (p = 0.028). Eyes with macular edema had average central macular thickness 329.89 ± 80.98 m[Formula: see text]; intraretinal cysts, sub retinal fluid, hyper-reflective foci, epiretinal membrane, and vitreomacular traction were found in 87.2%, 6.4%, 85.1%, 10.6%, and 6.4% of eyes, respectively. Diabetic retinopathy screening overwhelms health systems and is typically based on color fundus photographs, with high false-positive rates for the detection of diabetic macular edema. The present, semi-automated strategy comprising artificial intelligence algorithms integrated with smartphone-based retinal cameras could improve screening in low-resource settings with limited availability of ocular coherence tomography, allowing increased access rates and ultimately contributing to tackle preventable blindness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo-SP, Brazil. fernandokmalerbi@gmail.com.
- Hospital de Olhos Beira Rio, Itabuna, BA, Brazil.
- Faculdade de Medicina Santo Agostinho, Itabuna, BA, Brazil.
- Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo-SP, Brazil.
- IPEPO Vision Institute, São Paulo, SP, Brazil.
- Universidade Estadual de Santa Cruz, Ilheus, BA, Brazil.
Zitieren
APA
Malerbi, F. K., Mendes, G., Barboza, N., Morales, P. H., Montargil, R., & Andrade, R. E. (2022). Diabetic Macular Edema Screened by Handheld Smartphone-based Retinal Camera and Artificial Intelligence. Journal of Medical Systems, 46(1). https://doi.org/10.1007/s10916-021-01795-8
Vancouver
Malerbi FK, Mendes G, Barboza N, Morales PH, Montargil R, Andrade RE. Diabetic Macular Edema Screened by Handheld Smartphone-based Retinal Camera and Artificial Intelligence. Journal of Medical Systems. 2022;46(1). doi:10.1007/s10916-021-01795-8
BibTeX
@article{Malerbi2022,
author = {Malerbi, Fernando Korn and Mendes, Giovana and Barboza, Nathan and Morales, Paulo Henrique and Montargil, Roseanne and Andrade, Rafael Ernane},
title = {Diabetic Macular Edema Screened by Handheld Smartphone-based Retinal Camera and Artificial Intelligence},
journal = {Journal of Medical Systems},
year = {2022},
volume = {46},
number = {1},
doi = {10.1007/s10916-021-01795-8}
}
EUVIMED